It is a **chronic metabolic disease** associated with: Type 2 Diabetes Hypertension Dyslipidemia Cardiovascular disease Fatty liver disease (MASH) Sleep apnea Despite effective therapies, many patients hesitate to start treatment because injectable medications can affect adherence
Clinical trial data shows average loss of approximately one percent of body weight per month during months six through twelve, ultimately reaching 15 to 16 percent total body weight loss by the end of year one
Specifications Compound: Melanotan 2 Quantity: 10 mg Purity: 99% (HPLC Certified) Form: Lyophilized powder Appearance: White to off-white powder Solubility: Soluble in laboratory-grade sterile water COA: Included in product image gallery Intended Use This peptide analog is supplied strictly for in-vitro laboratory research
Results copied to clipboard
32, 33 Although numerous stimulants can affect PSCs including activation of some G-protein-coupled receptors (PGE2, angiotensin, CCK-A, CCK-B), 34, 35, 36, 37, 38, 39 it is unknown if GLP-1R occurs on PSC either in normal pancreas or pancreatic disease states or, whether PSCs are activated in AP or CP, or if it does occur, whether the GLP-1R agonists affect the PSC signaling cascade, growth or ability to release inflammatory mediators
